de Abood M, de Castillo Z, Guerrero F, Espino M, Austin K L
Hematology Section, Social Security Hospital, Madrid.
Contraception. 1997 Nov;56(5):313-6. doi: 10.1016/s0010-7824(97)00156-x.
Forty-three homozygous (SS) female sickle cell anemic patients with a history of at least one painful crisis per month and desiring a reversible contraceptive were administered DMPA/3 months or Microgynon monthly. A third group of 16 surgically sterilized patients served as control. Patients were followed for 1 year to assess possible effects of the contraceptives on the patients' painful crises. No changes were observed in any of the groups in the hematological parameters. At the end of the study, 70% of the patients receiving DMPA were pain-free and only 16% of those still reporting painful crises rated them as intense. Patients receiving Microgynon also had an amelioration of the painful crises, although at a lower rate; after 12 months, 45.5% still experienced some crises. Although less marked than in the other groups, 50.5% of the control patients also reported an improvement of their painful crisis, which may be a result of closer medical care.
43名纯合子（SS）女性镰状细胞贫血患者，每月至少经历一次疼痛性危象且希望采用可逆性避孕方法，她们被给予了每3个月一次的醋酸甲羟孕酮（DMPA）或每月一次的复方炔诺酮片。第三组16名接受手术绝育的患者作为对照。对患者进行了1年的随访，以评估避孕药对患者疼痛性危象的可能影响。所有组的血液学参数均未观察到变化。研究结束时，接受DMPA的患者中有70%无疼痛，仍报告有疼痛性危象的患者中只有16%将其评为剧烈疼痛。接受复方炔诺酮片的患者疼痛性危象也有所改善，尽管比例较低；12个月后，45.5%的患者仍经历一些危象。尽管不如其他组明显，但50.5%的对照患者也报告其疼痛性危象有所改善，这可能是更密切医疗护理的结果。
